The CML and PV groups, the MPN subgroups, also showed higher NGAL levels than the control group; this difference was also not statistically significant (P = .54 and P = 1.000, respectively). The gene discussed is LCN2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.